Summary
(vi) independent of serology and cause of death, paraneoplastic cerebellar degeneration paraneoplastic disease (1-and 2-year survival estimates, 76% and 31%, respectively). The pathological findings of patients receiving standard treatment for small-cell lung cancer died earlier than a matched group of non-paraneofive HuAb positive paraneoplastic cerebellar degeneration patients examined at autopsy included diffuse encephaloplastic cerebellar degeneration small-cell lung cancer patients; (vii) (pathology) inflammatory infiltrates were far myelitis with severe loss of Purkinje cells in four patients, but no apparent Purkinje cell loss in one; three patients also more prominent in HuAb positive compared with HuAb negative paraneoplastic cerebellar degeneration patients, in

Introduction
'Subacute cerebellar degeneration associated with neoIn 1982, Henson and Urich classified paraneoplastic plasms', now usually called paraneoplastic cerebellar cerebellar degeneration according to the presence or absence degeneration, is a clinico-pathological concept established of inflammatory infiltrates. The discovery that some patients by Brain and Wilkinson (1965) , and characterized by the with paraneoplastic cerebellar degeneration harbour, in their subacute onset of cerebellar dysfunction (gait difficulty serum and CSF, antibodies against neuronal proteins and limb ataxia), sometimes associated with dysarthria, expressed by the tumour (onconeural antigens) (Trotter et al., dysphagia, nystagmus, mental changes, and muscular and 1976; Greenlee and Brashear, 1983; Graus et al., 1985 ; sensory deficits. The pathological hallmark is a diffuse loss Jaeckle et al., 1985; Luque et al., 1991) , has lead some of Purkinje cells, usually accompanied by thinning of the investigators (Hammack et al., 1990; Dalmau and Graus, molecular and granular layers, and degeneration of the 1995; to divide paraneoplastic cerebellar dentate, olivary nuclei and long tracts of the spinal cord degeneration into subsets according to the presence or absence (Brain and Wilkinson, 1965) . In some patients, inflammatory of specific antibodies. While the role of these antibodies in infiltrates are found in cerebellum and other areas of the the pathogenesis of paraneoplastic cerebellar degeneration is neuraxis, but not in the Purkinje cell layer (Brain et al., unknown, specific onconeural antibodies are associated with 1951; Vick et al., 1969) . Cancers of the lung, ovary, breast specific neoplasms, often allowing early detection of the and lymphoma are the most frequent causal neoplasms. Brain tumour (Hammack et al., 1990; Dalmau et al., 1992a; and Wilkinson (1965) included 13 clinically observed cases Peterson et al., 1992) . In addition, paraneoplastic cerebellar and six patients with autopsy studies in their original descripdegeneration associated with specific onconeural antibodies tion, and pointed out that subacute cerebellar degeneration differ neuropathologically and clinically. For example, antiassociated with neoplasm 'is both clinically and pathologically less well defined than its name may imply'.
Yo antibodies are usually associated with: (i) ovarian or breast cancer; (ii) severe neurological disability that is of The diagnosis of small-cell lung cancer was confirmed itself rarely the cause of death; and (iii) a total, or near total histologically before death in 50 patients. Three patients had loss of Purkinje cells with few or no inflammatory infiltrates tissue diagnosis established at autopsy. Four patients without in the cerebellum, but marked inflammatory infiltrates in histological evidence of small-cell lung cancer, were included the tumour (Hetzel et al., 1990; Peterson et al., 1992;  in the study on the basis of the presence of chest or CT Verschuuren et al., 1996) . By contrast, Hu antineuronal radiological abnormalities suggestive of a neoplasm and the antibodies (HuAb) usually indicate a more widespread detection of HuAb, which is known to be a serological disorder called paraneoplastic encephalomyelopathy and marker for small-cell lung cancer (Dalmau et al., 1990 , sensory neuronopathy, almost always associated with small1992a; Kiers et al., 1991) . cell lung cancer (Anderson et al., 1988; Using these criteria, 57 patients with small-cell lung cancer 1992b). These patients also differ from anti-Yo patients in and paraneoplastic cerebellar degeneration were identified; that the HuAb positive patients often die from the neurological 32 were examined by at least one of the authors; information disorder, and have extensive inflammatory infiltrates in the on the other 25 patients whose serum was referred for nervous system and neuronal degeneration not restricted to assay, was obtained from records sent by referring physicians Purkinje cells of the cerebellum (Graus et al., 1987; Anderson or by telephone and letter interviews with the families et Dalmau et al., 1992b Dalmau et al., , 1995 (Clouston et al., 1992; Motomura et al., 1995) .
Sera and tissues
To determine the clinical implication of the presence or Serum from paraneoplastic cerebellar degeneration patients absence of antineuronal antibodies in patients presenting with was obtained at diagnosis of the neurological disorder, and paraneoplastic cerebellar degeneration, we examined the sera from control subjects at diagnosis of small-cell lung cancer; of 57 patients with paraneoplastic cerebellar degeneration all sera were kept frozen at -70°C. Cerebral cortex, and small-cell lung cancer for autoantibodies, including cerebellum and non-neural tissue (liver, kidney) were HuAb, P/Q-and N-type voltage-gated calcium channel obtained from neurologically normal individuals within 6 h antibodies. Patients with and without HuAb were compared after death, embedded in optimal cutting temperature with respect to neurological symptoms, course of the compound (OCT, Miles, Elkhart, Ind., USA), snap frozen in neurological disorder, response to treatment, tumour isopentane chilled by liquid nitrogen, and stored at -70°C. prognosis, and cause of death.
Isolation of cortical neurons and Purkinje cells and purification of recombinant HuD (an antigen recognized by HuAb) were obtained as previously reported (Dalmau and Patients and methods Rosenfeld, 1995; Manley et al., 1995) .
Inclusion criteria
The sera of all small-cell lung cancer patients (57 with Patients included in the study had (i) presenting symptoms paraneoplastic cerebellar degeneration and 109 without of paraneoplastic cerebellar degeneration, (ii) a small-cell paraneoplastic cerebellar degeneration) and 45 normal lung cancer identified before or after the development of individuals (blood bank donors) were examined for neurological symptoms and (iii) serum available for antineuronal antibodies at the Memorial Sloan-Kettering immunological studies.
Cancer Center (see below). In addition, sera were examined Patients were considered to have paraneoplastic cerebellar for P/Q-and N-type voltage-gated calcium channel antibodies degeneration if (i) cerebellar dysfunction was not ascribable to at the Institute of Molecular Medicine, Oxford; they structural lesions such as brain or leptomeningeal metastases, included, 50 sera from small-cell lung cancer patients with cerebellar infarcts, or other identifiable neurodegenerative, paraneoplastic cerebellar degeneration (seven sera were no toxic, metabolic or iatrogenic diseases, and (ii) the cerebellar longer available), and 49 randomly selected sera of the syndrome was the initial or main clinical manifestation (if 109 small-cell lung cancer patients without paraneoplastic other neurological symptoms were present, these were mild cerebellar degeneration. Clinical information was concealed at presentation, or developed later). Clinical disability at from investigators interpreting the results of the studies (J.D., presentation was estimated using the modified Rankin Scale (Uchuya et al., 1996) . B.L. and J.N.-D.).
phosphate buffer pH 7.4 containing 0.1% Triton X-100,
Immunohistochemistry
before counting. All steps were performed at 4°C. The Immunohistochemical studies on sections of human cerebral specific binding was calculated from the total 125 I-ω-CmTx cortex, cerebellum and non-neural tissues, using serial precipitated minus the non-specific binding determined by dilutions (starting at 1 : 500) of sera from patients and performing the assay in the presence of excess unlabelled controls, were carried out as previously reported (Dalmau ω-CmTx (100 nM). Each sample was examined twice for et al., 1992a) .
this assay and the final titre taken as the average of both values. To determine N-type voltage-gated calcium channel antibodies we used 125 I-ω-conotoxin GVIA ( 125 I-ω-CgTx),
Western blotting
with an assay identical to the one described above, except Western blot studies included proteins from isolated cortical that homogenate of human frontal cortex was used as a neurons (100 µg/lane), Purkinje cells (100 µg/lane), and HuD source of antigen. Each sample was examined once for purified protein (2.3 µg/lane). The indicated amounts of this assay. proteins were electrophoretically separated in a 10% sodium dodecyl sulphate-polyacrylamide gel and transferred to nitrocellulose (Towbin et al., 1979) . After blocking with 5%
Criteria for the presence of autoantibodies
Carnation milk (Carnation Company, Calif., USA) and 10% Sera were considered positive for HuAb when they (i) normal goat serum (Cappel, West Chester, Pa., USA), strips specifically reacted with neuronal nuclei at dilutions were sequentially incubated with the patient's serum (serial greater than 1 : 500 (reactivity at lower dilutions, sometimes dilutions, in 10% normal goat serum, starting at 1 : 1000) associated with glial staining, was considered nonspecific), for 12 h at room temperature, biotinylated goat anti-human and (ii) identified a set of 35 to 40 kDa proteins on IgG (Vector Labs, Burlingame, Calif., USA) diluted 1 : 2000 immunoblots of cerebral cortex neurons and Purkinje cells in 10% normal goat serum, for 1 h at room temperature, or reacted with immunoblots of recombinant HuD protein. and the avidin-biotin-peroxidase complex (Vector Labs) for
Immunoblot reactivity was visually evaluated; a serum was 30 min at room temperature. The substrate staining was defined as having a low HuAb titre when reactivity could developed with 0.05% diaminobenzidine tetrahydrochloride only be detected at dilutions Ͻ1 : 10 000; a high HuAb (Sigma, St Louis, Mo., USA), 0.5% Triton X-100, and 0.01% titre was defined as positive reactivity at serum dilutions hydrogen peroxide in PBS (phosphate-buffered saline). Sera Ͼ1 : 10 000. from normal individuals and control small-cell lung cancer
For the P/Q-and N-type voltage-gated calcium channel patients were similarly handled and used at the same dilutions. assays, each serum was defined as positive if the titre was Ͼ3 SDs above the mean for 20 healthy controls (20 pM for the former and 30 pM for the latter assay).
Detection and quantification of P/Q-and N-type voltage-gated calcium channel antibodies
To determine P/Q-type voltage-gated calcium channel anti-
Statistics
bodies, synthetic ω-conotoxin MVIIC (ω-CmTx) was Statistical analyses were performed using Statview 4.5 obtained from the Peptide Institute Inc (European Distributor, (Abacus Concepts, Berkeley, Calif., USA). Data pertaining Scientific Marketing, UK). 125 I-labelled ω-CmTx ( 125 I-ω-to patient demographics, symptom duration, and outcome CmTx) was purchased from Amersham International were analysed using the Student's t test and the Mann-(Amersham, UK; specific activity 2000 Ci/mmol). Human Whitney U test. Post hoc testing was performed using cerebellum obtained at autopsy of a neurologically normal Fisher's protected least-significant difference. Nominally individual was homogenized in 25 mM Tris-HCl/5 mM characterized outcomes were compared using contingency HEPES buffer, pH 7.4, containing 0.32 M sucrose, 1 µM table analysis including the χ 2 test and Fisher's exact test. pepstatin, 2 µM leupeptin, 0.1 mM phenylmethysulphonylKaplan-Meier estimates of overall survival, and survival fluoride and 20 µg/ml soybean trypsin inhibitor, and centrifollowing the diagnosis of cancer were compared using a fuged. The resulting membrane pellets were resuspended in stratified Mantel-Haenszel statistic. Statistical significance the same buffer with 2% digitonin and agitated for 1 h at was defined as P Ͻ 0.05. 4°C. The supernatant was separated by centrifugation at 13 000 r.p.m. for 10 min. Cerebellum extract (5 µl) containing~5 fmol of binding sites, was labelled with 125 I-ω-CmTx
Results
for 2 h (0.1 nM) and incubated overnight with serum
Laboratory findings
(1.25-10 µl diluted 1 : 10) from small-cell lung cancer patients with paraneoplastic cerebellar degeneration or con-
Antineuronal antibodies
The serum of 25 paraneoplastic cerebellar degeneration trols. Excess goat anti-human IgG serum was then added for 1 h at 4°C to precipitate serum antibodies. Each sample was patients had high immunoblot titres of HuAb; four had low titres, and 28 were negative (Fig. 1) . Of 109 small-cell lung centrifuged and the pellets washed twice with 20 mM Fig. 1 Western blot of HuD. Immunoblots of HuD reacted with serial dilutions of serum from a patient with paraneoplastic cerebellar degeneration and a high titre of HuAb (lanes 2), serum from a patient with paraneoplastic cerebellar degeneration and low titre of HuAb (lanes 3), and serum from a smallcell lung cancer patient without paraneoplastic symptoms but with low titre of HuAb (lanes 5). Note the difference of reactivity between the patient with high titre of HuAb (lanes 2) and the two patients with low titre of HuAb (lanes 3 and 5). Lane N corresponds to serum from a normal individual; lane 1, serum from a patient with paraneoplastic cerebellar degeneration without HuAb, and lane 4, serum from a small-cell lung cancer patient without HuAb and no paraneoplastic symptoms. Note the absence of HuD reactivity in these three sera (lanes N, 1 and 4).
cancer patients without paraneoplastic cerebellar degeneration presence or absence of HuAb, we established two groups of patients; those with high titres of HuAb (HuAb positive or paraneoplastic encephalomyelitis and sensory neuropathy, 19 (17%) had low immunoblot titres of HuAb, and 90 were paraneoplastic cerebellar degeneration), and those without, or with low, titres of HuAb (HuAb negative paraneoplastic negative. All 45 sera from normal individuals were negative.
All HuAb positive sera reacted immunohistochemically cerebellar degeneration). We included four patients with paraneoplastic cerebellar degeneration and low titres of HuAb with cerebral cortical neurons and Purkinje cells, but not with non-neural tissue, as previously reported ( Fig. 2A) in the later group because (i) the amount of HuAb was similar, or lower, than in 17% small-cell lung cancer patients . Immunoreactivities other than HuAb were identified in the serum of 14 patients with small-cell without paraneoplastic symptoms, and (ii) previous studies have shown that the HuAb, at low titre, is a marker of the lung cancer and paraneoplastic cerebellar degeneration, and in the serum of 10 patients with small-cell lung cancer without presence of a small-cell lung cancer rather than paraneoplastic symptoms (Dalmau et al., 1990; . paraneoplastic symptoms; they included, immunostaining of the cytoplasm of basket cells (five patients, one with hightitre HuAb), cytoplasm of neurons or Purkinje cells (six patients), nuclei of glial cells (eight patients), cytoplasm of
Voltage-gated calcium channel antibodies
Twelve of 50 paraneoplastic cerebellar degeneration patients glial cells (one patient), and non-neuronal specific nuclear immunostaining (four patients). Due to the variety of tested (24%) had P/Q-type voltage-gated calcium channel antibodies; nine of these patients (18% of the 50) also had reactivities, the small number of patients with a specific pattern of reactivity, and the fact that similar reactivities were N-type voltage-gated calcium channel antibodies. No patient had N-type voltage-gated calcium channel antibodies in detected in patients without paraneoplastic symptoms, the clinical implication of the presence of these antibodies was isolation. Among the 49 small-cell lung cancer patients without paraneoplastic cerebellar degeneration (control not investigated.
To determine the clinical significance of classifying group), one patient (2%) had P/Q-, but no N-type voltagegated calcium channel antibodies (Fig. 3 ). paraneoplastic cerebellar degeneration according to the and Zeromski, 1965) demonstrating reactivity of the serum of a patient with lung cancer and paraneoplastic sensory neuropathy with a section of guinea pig cerebral cortex. Note that the reactivity is similar to that of the HuAb (A) characterized by predominant immunolabelling of the neuronal nuclei (sparing the nucleoli) and weaker reactivity with the cytoplasm of neurons. (B has been reproduced with permission.)
Fig. 3
Quantification of P/Q-and N-type voltage-gated calcium channel (VGCC) antibodies in 50 small-cell lung cancer (SCLC) patients with paraneoplastic cerebellar degeneration (PCD) and 49 smallcell lung cancer patients without paraneoplastic cerebellar degeneration. Twelve (24%) paraneoplastic cerebellar degeneration patients had P/Q type voltage-gated calcium channel antibodies; nine (18%) of these patients had also N-type voltage-gated calcium channel antibodies. Only one small-cell lung cancer patient (2%) without paraneoplastic cerebellar degeneration had P/Q-type voltage-gated calcium channel antibodies. Sera were defined positive for P/Q type (MVIIC) voltage-gated calcium channel antibodies if the titre was Ͼ3 SDs (20 pM) above the mean for 20 healthy controls. Sera were defined positive for N-type (GVIA) voltage-gated calcium channel antibodies if the titre was Ͼ3 SD (30 pM) above the mean for the same healthy controls. LEMS ϭ Lambert-Eaton myasthenic syndrome. HuAb ϩ PCD ϭ PCD patients with high titres of HuAb; HuAb -PCD ϭ PCD patients without HuAb or with low titres of HuAb. PWM ϭ periventricular white matter changes. Infl. ϭ inflammatory changes (increased proteins and/or pleocytosis). Abn 1 ϭ abnormal T 2 -signal in the pons and right internal capsule in a patient with PCD, opsoclonus and encephalopathy; Abn 2 ϭ abnormal T 2 -signal in the right insula of a patient with limbic encephalopathy; Abn 3 ϭ transient T 2 -abnormalities in the right temporal and semioval areas of a patient with limbic encephalopathy. *Excludes patients with LEMS or isolated diplopia. † Seven HuAb ϩ PCD patients: diplopia (four patients), anosmia (one), facial weakness with signs of denervation (two), oculomotor palsy (one), dysphagia (four), opsoclonus (two), palatal myoclonus (one), spontaneous slow vertical eye movements (one), sensory loss in trigeminal nerve distribution (one). ‡ Two HuAb -PCD patients: diplopia (two patients), head bobbing (one), horizontal conjugate gaze palsy (one).
that nine out of 14 HuAb positive paraneoplastic cerebellar
Clinical features degeneration (64%) were women and 12 out of 17 HuAb
Age and sex negative paraneoplastic cerebellar degeneration (71%) were There was no age difference between the HuAb positive and men (P ϭ 0.05, χ 2 ϭ 3.770). The 109 small-cell lung cancer HuAb negative paraneoplastic cerebellar degeneration groups controls were 57 men and 52 woman (i.e. 52% male). (Table 1 ). The HuAb positive group contained more women, 13 out of 25 (52%), and the HuAb negative more men, 26 out of 32 (81%) (P Ͻ 0.01, χ 2 ϭ 6.983).
Features relating to the paraneoplastic cerebellar
Thirty-one paraneoplastic cerebellar degeneration patients (17 men, 14 women) were from USA and 26 (21 men, five degeneration Because neurological symptoms preceded the cancer women) from Europe (Spain 15, France 10, and Germany one). The low prevalence of women with small-cell lung diagnosis in 49 patients (22 HuAb positive and 27 HuAb negative paraneoplastic cerebellar degeneration), most cancer in the European patients reflects the low exposure to tobacco smoking among women of that age (i.e. all 15 patients underwent extensive blood and CSF analysis, and radiological evaluation of the nervous system, chest and Spanish patients were men) (Ruigomez et al., 1995) . When the patients from the USA were considered, we found abdomen either as part of the neurological diagnosis or as tumour staging (Table 1 ). All patients had neuroradiological of sensory neuropathy was significantly associated with the presence of HuAb (P Ͻ 0.002, χ 2 ϭ 9.619). studies (57 patients) and/or CSF analysis (45) without evidence of intracranial or leptomeningeal metastases.
Typically, patients were disabled and had to make substantial lifestyle modifications. At initial neurological Cerebellar atrophy was identified at onset in only one patient who had diffuse cerebral atrophy. Signs of cerebellar atrophy evaluation, the HuAb positive paraneoplastic cerebellar degeneration cohort were more severely disabled than the were identified 6 months after symptom development in nine patients; the MRI of two patients remained normal 2 years HuAb negative with median Rankin disability scores of 4 and 3, respectively, but this difference was not significant, after developing paraneoplastic cerebellar degeneration.
Neurological complaints antedated the cancer diagnosis by P ϭ 0.10. However, 18 of 25 HuAb positive (72%) and 11 of 32 HuAb negative paraneoplastic cerebellar degeneration a median of 3 months (range 1-10 months for HuAb positive paraneoplastic cerebellar degeneration; 1-26 months for patients (34%) eventually required assistance in performing activities of daily living (P Ͻ 0.005, χ 2 ϭ 7.950). HuAb negative paraneoplastic cerebellar degeneration). In eight patients (three with HuAb positive and five with HuAb negative paraneoplastic cerebellar degeneration) neurological symptoms developed after tumour diagnosis (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Incidence and features of Lambert-Eaton months, median 5 months). At the time of tumour diagnosis, myasthenic syndrome in patients with most patients had limited stage disease (cancer confined to the chest) ( Table 1) .
paraneoplastic cerebellar degeneration
Lambert-Eaton myasthenic syndrome with proximal motor Ataxia was detected at presentation in all paraneoplastic cerebellar degeneration patients. Nystagmus, usually weakness, decreased or absent reflexes, dry mouth, or diplopia (two cases) was clinically identified in eight patients (four asymptomatic, was present in 64% HuAb positive and 56% HuAb negative paraneoplastic cerebellar degeneration HuAb positive and four HuAb negative paraneoplastic cerebellar degeneration). Seven of them had Lambert-Eaton patients. Dysarthria, sufficient to interfere with communication, was present in 52% HuAb positive and 59% HuAb myasthenic syndrome confirmed electrophysiologically (Ͼ100% increase of compound muscle action potential after negative patients. Diplopia was an early and frequent symptom in both groups of patients. maximum voluntary contraction or high-frequency repetitive nerve stimulation), and in one repetitive nerve stimulation Overall, 80% HuAb positive and 37.5% HuAb negative paraneoplastic cerebellar degeneration patients developed was not obtained. One additional HuAb positive patient had electrophysiological signs of Lambert-Eaton myasthenic extracerebellar symptoms during the course of the disease (P Ͻ 0.002, χ 2 ϭ 10.296). Extracerebellar symptoms were syndrome, but suffered from a devastating cerebellar syndrome which masked Lambert-Eaton myasthenic often detectable within the first month of the disease (Table  1) , but in some patients developed as the disease evolved.
syndrome symptoms (Table 2) . Among these nine patients with definite or probable Lambert-Eaton myasthenic Symptoms and signs of brainstem or cranial nerve dysfunction predominated in HuAb positive patients (P Ͻ 0.03, χ 2 ϭ syndrome, seven had serum available for assay for voltagegated calcium channel antibodies; all seven were positive for 4.993). In addition, one patient with HuAb had bilateral optic neuritis of uncertain origin. P/Q-type voltage-gated calcium channel antibodies, and four of them also had N-type voltage-gated calcium channel Ten (40%) HuAb positive paraneoplastic cerebellar degeneration patients developed a pure sensory neuropathy.
antibodies. In addition, P/Q-type voltage-gated calcium channel antibodies were identified in five HuAb negative Sensory deficits were present at the beginning of paraneoplastic cerebellar degeneration in nine patients and paraneoplastic cerebellar degeneration patients without clinical or electrophysiological (four patients) signs of developed later in one; symptoms evolved asymmetrically in five and were associated with pain in 7. Eventually, the lower Lambert-Eaton myasthenic syndrome; all five patients also had N-type voltage-gated calcium channel antibodies. extremities were involved in all 10 patients and the upper extremities in seven. One patient had painful dysaesthesias Overall, eight out of 57 (14%) small-cell lung cancer patients with paraneoplastic cerebellar degeneration had in the face; none developed sensory deficits in the abdomen or trunk. Electrophysiological studies obtained in seven symptoms that led to Lambert-Eaton myasthenic syndrome being identified, compared with none of 49 small-cell lung patients showed absent sensory potentials in six (one also had denervation) and normal findings in one. Motor nerve cancer patients without paraneoplastic cerebellar degeneration (P Ͻ 0.01, χ 2 ϭ 7.439). Regardless of the presence of conduction studies were normal or borderline in all patients. The sensory neuropathy became severe in four patients and symptoms or electrophysiological findings of Lambert-Eaton myasthenic syndrome, 12 of 50 (24%) paraneoplastic remained mild or moderate in the other six. By contrast, only two HuAb negative paraneoplastic cerebellar degeneration cerebellar degeneration patients harboured P/Q-type voltagegated calcium channel antibodies compared with one out of patients (6%) developed mild distal symmetric sensory neuropathy in the lower extremities (decreased vibratory 49 (2%) small-cell lung cancer patients without paraneoplastic cerebellar degeneration (Fig. 3) . Antibodies to voltage-gated sensation and absent ankle jerks). Comparing these patients with the HuAb positive patients, the incidence and severity calcium channel appeared to be particularly high in the HuAb negative paraneoplastic cerebellar degeneration group, in myasthenic syndrome. No neurological response was observed in nine other patients (five HuAb positive and four which 10 out of 28 (36%) had P/Q-type voltage-gated calcium channel antibodies (P Ͻ 0.001, χ 2 ϭ 16.5) and eight of HuAb negative paraneoplastic cerebellar degeneration) who received similar treatment for the tumour and plasma them (29%) also had N-type voltage-gated calcium channel antibodies (P Ͻ 0.0001; χ 2 ϭ 20.1) ( Table 2) .
exchange. Two patients with Lambert-Eaton myasthenic syndrome responded to therapy; both received plasma exchange, and one 3,4-diaminopyridine. No specific treatment for the
Survival and cause of death
Lambert-Eaton myasthenic syndrome was given to two No significant differences were observed between survival patients; one had severe paraneoplastic cerebellar (Table 4) or Kaplan-Meier survival estimates of HuAb degeneration and Lambert-Eaton myasthenic syndrome positive and negative paraneoplastic cerebellar degeneration diagnosed electrophysiologically, and the other presented patients (data not shown). In total, 31 paraneoplastic with mild symptoms of Lambert-Eaton myasthenic syndrome cerebellar degeneration patients (14 HuAb positive and 17 3 months before developing severe paraneoplastic cerebellar HuAb negative) received treatment for limited-stage smalldegeneration and prior to the diagnosis of small-cell lung cell lung cancer; 1-and 2-year survival estimates following cancer. Treatment, if any, and responses are unknown in the cancer diagnosis were 46% (confidence interval 28%-the other four patients with symptoms of Lambert-Eaton 64%) and 28% (confidence interval 10%-46%), respectively. myasthenic syndrome.
Survival estimates at 1-and 2-years for an age-, sexand treatment-matched cohort of 59 neurologically normal patients with limited-stage small-cell lung cancer were 76%
Response of paraneoplastic cerebellar
(confidence interval 65%-87%) and 31% (confidence interval degeneration and small-cell lung cancer to 19%-43%), respectively (Fig. 4) . This finding indicates that 1 year survival for small-cell lung cancer patients with
cancer therapy or immunotherapy
The responses of paraneoplastic cerebellar degeneration and paraneoplastic cerebellar degeneration (regardless of the HuAb status) is less likely than 1 year survival for smallsmall-cell lung cancer to treatment are shown in Tables 3  and 4 , respectively. Overall, four patients (one with HuAb cell lung cancer patients without paraneoplastic cerebellar degeneration. positive and three with HuAb negative paraneoplastic cerebellar degeneration) had partial neurological improveHuAb positive paraneoplastic cerebellar degeneration patients were significantly more likely than HuAb negative ment; all received treatment for the tumour and three had plasma exchange. Two of these patients (one HuAb positive to die of neurological disease (P Ͻ 0.001, χ 2 ϭ 12.907) ( Table 4 ). Thirteen of 20 HuAb positive died of neurological and one HuAb negative paraneoplastic cerebellar degeneration) had Lambert-Eaton myasthenic syndrome that causes, including respiratory muscle failure due to lower motor neuron dysfunction (two patients needed ventilatory responded to therapy (see above); thus apparent improvement could have been due to amelioration of Lambert-Eaton support), autonomic failure (two) and progressive diffuse 
Fig. 4
Kaplan-Meier survival curves of 31 small-cell lung cancer patients (SCLC) with paraneoplastic cerebellar degeneration (PCD), and an age-, sex-, tumour stage-and treatment-matched cohort of 59 small-cell lung cancer patients without paraneoplastic cerebellar degeneration. The thick line represents small-cell lung cancer patients with paraneoplastic cerebellar degeneration and the thin line small-cell lung cancer patients without paraneoplastic cerebellar degeneration. X ϭ censor times for small-cell lung cancer patients with paraneoplastic cerebellar degeneration; ϩ ϭ censor times for small-cell lung cancer patients without paraneoplastic cerebellar degeneration. Note that 1-year survival in small-cell lung cancer patients with paraneoplastic cerebellar degeneration (combined group of 14 HuAb positive and 17 HuAb negative) is less likely than 1-year survival in small-cell lung cancer patients without paraneoplastic cerebellar degeneration.
encephalopathy with predominant brainstem dysfunction cell lung cancer dissemination at death in HuAb negative paraneoplastic cerebellar degeneration patients was similar (nine). Only two of 20 HuAb negative paraneoplastic to that in the control patients with initially limited small-cell cerebellar degeneration patients died as a result of progressive lung cancer. Of these 59 patients, 53 are deceased; 41 had neurological disease (see pathology findings in Table 5) . disseminated disease at death, 10 had small-cell lung cancer By contrast, five HuAb positive and 16 HuAb negative confined to the thorax, and two had no evidence of tumour. paraneoplastic cerebellar degeneration patients died from Five HuAb positive and seven HuAb negative paratumour progression. Patients with HuAb were also less likely neoplastic cerebellar degeneration patients were alive at last than HuAb negative patients to have extensive small-cell follow-up. One HuAb positive patient has no evidence of lung cancer at the time of death (P Ͻ 0.007, χ 2 ϭ 7.501) (Table small-cell lung cancer (49 months after diagnosis), two have 4). At death, 12 HuAb positive paraneoplastic cerebellar limited and stable disease (12 and 16 months), one has stable degeneration patients had either small-cell lung cancer limited liver metastases (12 months), and details are unknown for to the thoracic cavity (10) or had no evident tumour (two); one patient. Six HuAb negative paraneoplastic cerebellar seven had extensive disease but in two the extent of metastatic degeneration patients are currently without evidence of smalldissemination was microscopic, being confined to mesenteric cell lung cancer (median 13 months, range 9-30 months), lymph nodes examined at autopsy. The extent of tumour and one is alive with limited and stable disease (6 months). infiltration was unknown at the time of death in one HuAb positive patient. In the HuAb negative paraneoplastic cerebellar degeneration subset, one patient had no evidence Pathology of tumour at death, three had limited small-cell lung cancer, All paraneoplastic cerebellar degeneration patients with a high titre of HuAb had inflammatory infiltrates involving and 16 had widely disseminated disease. The extent of small- Honnorat et al., 1996) . HuAb ϩ PCD ϭ PCD patients with high titres of HuAb; HuAb -PCD ϭ PCD patients without HuAb, or with low titres of HuAb.
multiple areas of the nervous system (Table 5) ; perivascular fied in only a few vessels of the cerebellar white matter; there was no apparent Purkinje cell loss, and the cerebellar lymphocytic cuffing was always present in those areas, in association with variable interstitial inflammatory infiltrates cortex and nuclei appeared normal. In two HuAb negative paraneoplastic cerebellar degeneraand gliosis (Fig. 5) . Four of the five HuAb positive patients had moderate to severe loss of Purkinje cells (Fig. 5A tion patients, the pathological findings were largely restricted to the cerebellum where Purkinje cell loss was prominent in and B) associated with inflammatory infiltrates in the deep cerebellar nuclei, particularly dentate (Fig. 5C) ; infiltrates of both cases (Fig. 5D ), and associated with gliosis in one; no inflammatory infiltrates were identified in the cerebellum, T cells adjacent to the Purkinje cell layer were identified in one of these patients (Fig. 5A) . In another HuAb positive brainstem or brain. The spinal cord, examined in one of these two patients, showed degeneration of the spinal tracts patient (Table 5 , autopsy 3), perivascular cuffing was identi- (predominantly corticospinal) without inflammatory infiltparaneoplastic limbic encephalitis (Alamowitch et al., 1997) . rates or loss of neurons; the patient did not have any Previous American series suggested that paraneoplastic corresponding clinical signs.
neurological symptoms associated with HuAb affect women A third HuAb negative paraneoplastic cerebellar degeneramore than men (Dalmau et al., 1992b) , but the high prevalence tion patient had extensive Purkinje cell loss associated with of men with HuAb negative paraneoplastic cerebellar perivascular inflammatory infiltrates in several areas of the degeneration has not been reported. neuraxis. The serum of this patient contained antibodies, Extracerebellar symptoms with paraneoplastic cerebellar called CV2, which specifically react with the nervous system degeneration were noted by Greenfield (1934) and Brain and have been reported to be associated with paraneoplastic et al. (1951) , and emphasized by Brain and Wilkinson encephalitis (data not shown) (Antoine et al., 1993; Honnorat (1965) , who found that 21% of their paraneoplastic cerebellar et al., 1996) . None of the other seven patients with postdegeneration patients had early sensory symptoms (usually mortem studies harboured this antibody in their serum.
with pain) and other abnormalities, including dementia, muscular weakness, dysphagia, nystagmus and abnormal reflexes. These investigators recognized that diplopia without Discussion evidence of ocular paralysis, was a frequent symptom of In patients with small-cell lung cancer, paraneoplastic paraneoplastic cerebellar degeneration. Brain et al. (1951) , cerebellar degeneration occurs with or without HuAb. The in discussing diplopia stated that 'Its occurrence in cortical presence or absence of these antibodies has clinical and cerebellar degeneration is not so unusual as textbook prognostic implications and characteristic pathological descriptions of the disease would suggest' and they added correlations. However, regardless of the HuAb status, at that, in most cases, it '. . . appears to have been due to lack least 16% of patients develop Lambert-Eaton myasthenic of balance rather than to paralysis of eye muscles.' In some syndrome, and 36% of those without HuAb harbour P/Q-or of our patients with signs of brainstem encephalopathy, we N-type voltage-gated calcium channel antibodies.
attributed the diplopia to brainstem dysfunction; in others, Wilkinson and Zeromski (1965) first reported antineuronal the diplopia was clearly attributable to Lambert-Eaton antibodies in patients with paraneoplastic neurological myasthenic syndrome (O'Neill et al., 1988) , but there were syndromes. The serum of four patients with small-cell lung patients with isolated and persistent diplopia, the cause of cancer and sensory neuropathy contained antibodies that which was either paraneoplastic cerebellar degeneration or appeared to react with neuronal cytoplasmic antigens. They uncertain. Diplopia is also a common finding in patients with suggested that 'it would be of interest to investigate sera anti-Yo associated paraneoplastic cerebellar degeneration and from patients with encephalomyelitic form of carcinomatous ovarian or breast cancer, where pathological changes in neuropathy for the presence of circulating anti-brain brainstem and Lambert-Eaton myasthenic syndrome are rare antibodies, particularly as lymphocytic infiltration is a (Hammack et al., 1990; Peterson et al., 1992) . prominent feature in these patients' (Wilkinson and Zeromski, CT and MRI imaging are important complementary studies 1965). They were correct (Graus et al., 1987; Anderson et al., to rule out other neurological complications of cancer, but 1988; Dalmau et al., 1992b) . Careful inspection of the they are normal or non-specific in the early stages of photomicrograph of the antibody reactivity identified by paraneoplastic cerebellar degeneration (Peterson et al., 1992; Wilkinson and Zeromski (1965) suggests that it was HuAb . Cerebellar atrophy, if present, occurs months (Fig. 2) . HuAb reacts with 35-40 kDa antigens expressed in after the neurological symptoms have stabilized. Even in neurons of the central and peripheral nervous system and in patients with HuAb and encephalomyelitis, the MRI is usually small-cell lung cancer (Graus et al., 1986; Dalmau et al., normal (Dalmau et al., 1992b) . Exceptions may occur if 1990, 1992a). A high titre of HuAb is usually associated there is limbic encephalopathy, in which case, abnormal with small-cell lung cancer and paraneoplastic contrast enhancement or T 2 -weighted abnormalities may be encephalomyelitis or sensory neuropathy, but 13% of these found in the medial aspect of the temporal lobes (Dirr et al., patients have pure or predominant cerebellar findings at 1990; Lacomis et al., 1990; Dalmau et al., 1992b) , such as presentation (Dalmau et al., 1992b) . occurred in two of our patients. Almost one-half (44%) of patients with small-cell lung Similarly, although inflammatory changes (pleocytosis or cancer and paraneoplastic cerebellar degeneration harbour increased proteins) were identified in 87% HuAb positive and high titres of HuAb. This antibody when present in high 59% HuAb negative paraneoplastic cerebellar degeneration concentration defines a subset of patients different from the patients, these abnormalities did not permit differentiation seronegative cohort; HuAb positive patients are more likely between groups. As previously reported, CSF studies in to be women, have multifocal neurological disease (with paraneoplastic disorders are used mainly to rule out leptobrainstem encephalopathy and sensory neuropathy especially meningeal metastases and not to demonstrate antineuronal common), and be severely disabled. A similar association antibodies which, if present, are always detectable in serum between the presence of high-titre HuAb and development (Graus et al., , 1994 ; Dalmau of multifocal neurological disease has been found in smallcell lung cancer patients with symptom presentation of et al., 1992b) (data not shown). CSF pleocytosis, although not specific, should increase the clinical suspicion of a disease, and survive longer than patients without HuAb . paraneoplastic disorder (Dalmau and Posner, 1996) .
In most of our patients cerebellar symptoms stabilized Despite limited stage and less aggressive tumour behavior in the HuAb positive group, these patients had significantly spontaneously, leaving the patient substantially incapacitated. Although minor fluctuations in clinical symptoms were shorter life expectancies than small-cell lung cancer patients without paraneoplastic cerebellar degeneration, and death observed in a few patients, spontaneous remission is not a feature of this syndrome. Attempts to alleviate the severity usually occurred as a consequence of the neurological disease. By contrast, patients with paraneoplastic cerebellar degeneraof the cerebellar disorder, or halt its progression with a variety of immunomodulating interventions including corticosteroids, tion, but without HuAb, were likely to die from the tumour. Yet, for these patients also, survival was significantly shorter plasma exchange, and intravenous gammaglobulin were unsuccessful. Furthermore, efforts directed at controlling the than that of neurologically intact small-cell lung cancer controls, and not substantively different from that of HuAb underlying carcinoma, although often successful, had no significant impact on the course or severity of the paraneopositive patients. None of the paraneoplastic cerebellar degeneration patients without HuAb required ventilation or plastic cerebellar degeneration.
Among the 37 patients who had evaluable treatment developed severe dysphagia and autonomic dysfunction, but compared with patients without neurological symptoms, responses, only four had mild improvement of the cerebellar syndrome. Yet, two of these four patients had Lambertparaneoplastic cerebellar degeneration patients had a lower performance status, which is known to be a poor prognostic Eaton myasthenic syndrome that dramatically responded to treatment, as has been documented in other Lambert-Eaton factor in small-cell lung cancer (Spiegelman et al., 1989; Lassen et al., 1995; Rosenfeld et al., 1997) . myasthenic syndrome cases (Chalk et al., 1990) . This differential response to treatment of paraneoplastic syndromes of Two of the three patients (cases 1 and 2) described in detail by Brain and Wilkinson (1965) in their series of 19 the CNS and Lambert-Eaton myasthenic syndrome has been previously reported (Blumenfeld et al., 1991; Fueyo et al., patients with 'subacute cerebellar degeneration associated with neoplasms' may have had Lambert-Eaton myasthenic 1993; Goldstein et al., 1994) . The poor response of paraneoplastic cerebellar degeneration to therapy is consistent syndrome. Both patients, in addition to cerebellar ataxia, had mild cranial nerve dysfunction (diplopia, ptosis and facial with our impression, and that of others (Henson and Urich, 1982; Dalmau et al., 1992b; Graus et al., 1992 ; Uchuya weakness), proximal weakness of the lower limbs and decreased or absent reflexes. The resemblance of case 1 to a et al ., 1996) , that paraneoplastic disorders of the CNS, particularly when associated with small-cell lung cancer or myasthenic syndrome is supported by the treatment that these authors used, including Neostigmine and Mestinon (with HuAb, rarely respond to treatment. However, individual case reports describe responses to various treatments of most partial response to the first and unknown response to the latter); case 2 developed sluggish pupillary responses to light, paraneoplastic syndromes of the CNS (Satoyoshi et al., 1973; Paone and Jeyasingham, 1980; Brennan and Craddock, 1983;  and 'under anaesthetic he was extremely sensitive to muscle relaxants'. Considering the limitations of our diagnostic Cocconi et al., 1985; Burton et al., 1988; Batson et al., 1992; Counsell et al., 1994; Antoine et al., 1995; Cher et al., 1995;  interpretation, these two patients represented 20% of those with lung cancer in the series of Brain and Wilkinson, similar Stark et al., 1995) . In these reports, the underlying tumours are rarely small-cell lung cancer, and the paraneoplastic to the frequency of Lambert-Eaton myasthenic syndrome associated with paraneoplastic cerebellar degeneration in our disorders are usually limbic encephalopathy and opsoclonus, which may improve spontaneously even when the tumour is cohort of patients. Clouston et al. (1992) reported on nine patients with a small-cell lung cancer (Alamowitch et al., 1997) .
Our patients usually had tumours confined to the thorax pancerebellar syndrome, six of whom had Lambert-Eaton myasthenic syndrome and one of whom had increased at diagnosis. This may represent an anticipation phenomenon, where the development of the neurological disorder, parvoltage-gated calcium channel antibodies without LambertEaton myasthenic syndrome. In two patients, Lambert-Eaton ticularly in association with antineuronal antibodies, prompts an investigation for an occult malignancy. Although complete myasthenic syndrome was discovered only by neurophysiological testing. These authors identified 23 previously tumour responses were more frequently observed in the HuAb negative patients, the tumours of the HuAb positive reported patients with Lambert-Eaton myasthenic syndrome and paraneoplastic cerebellar degeneration, most of them patients remained limited during the course of the disease more often than those without HuAb. A larger number of with lung cancer. They concluded that the frequency of association of paraneoplastic cerebellar degeneration and paraneoplastic cerebellar degeneration patients is needed to demonstrate if this less aggressive tumour behavior results Lambert-Eaton myasthenic syndrome was higher than expected by chance and that the presence of voltage-gated from an anti-tumour effect of the HuAb immune response. A similar clinical impression has been obtained from studies calcium channel antibodies was not always confined to Lambert-Eaton myasthenic syndrome (Clouston et al., 1992) . of small-cell lung cancer patients without paraneoplastic symptoms but with low titre of HuAb (Dalmau et al., 1990) ;
Since then, a new immunoprecipitation assay has been reported by Motomura et al. (1995) for detecting antibodies to these patients are more likely to be female, have limited voltage-gated calcium channel in Lambert-Eaton myasthenic important because the motor weakness increases the deficits of paraneoplastic cerebellar degeneration or paraneoplastic syndrome using 125 I-ω-CmTx, which binds to P/Q-type voltage-gated calcium channel. These antibodies were found encephalomyelitis, and because Lambert-Eaton myasthenic syndrome responds to therapy (Newsom-Davis and Murray, in 85% of 66 serum samples from Lambert-Eaton myasthenic syndrome patients and were absent in 10 healthy and 40 1984; Chalk et al., 1990; Blumenfeld et al., 1991; Bain et al., 1996) . disease control patients. Although there is agreement that most Lambert-Eaton myasthenic syndrome patients harbour
The neuropathological findings of five paraneoplastic cerebellar degeneration patients with a high titre of HuAb P/Q-type voltage-gated calcium channel antibodies, another study (Lennon et al., 1995) identified similar antibodies in a are consistent with the protean clinical manifestations of the disorder; i.e. multifocal inflammatory infiltrates in cerebelmixed assortment of patients with different types of cancer either without or with paraneoplastic symptoms or antineurlum, brainstem, and dorsal nerve root and ganglia, along with variable gliosis, loss of neurons and secondary degeneration of onal antibodies. However, the clinical characterization of these neurological syndromes, the association with specific the posterior columns of the spinal cord. The extensive loss of Purkinje cells in four of these patients explained the types of tumours and the co-existence of Lambert-Eaton myasthenic syndrome were not reported. cerebellar findings; however, one patient with brainstem encephalitis (autopsy 3) characterized by opsoclonus and In patients with small-cell lung cancer, Lambert-Eaton myasthenic syndrome appears to segregate with paraneocerebellar signs had no significant loss of Purkinje cells. The pathological findings of the HuAb positive patients are plastic cerebellar degeneration, and is usually detectable when symptoms of paraneoplastic cerebellar degeneration characteristic of 'encephalomyelitis associated with cancer' (Henson et al., 1965) rather than a pure cortical cerebellar emerge. In support of the earlier studies (Satoyoshi et al., 1973; Clouston et al., 1992; Goldstein et al., 1994) suggesting degeneration (Henson and Urich, 1982) . The case 2 of Greenfield (1934) and cases 3 and 4 of an association between paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome, 16% of our Brain et al. (1951) are probably the first reported lung cancer patients with paraneoplastic cerebellar degeneration as a patients had Lambert-Eaton myasthenic syndrome. Furthermore, the fact that 24% of small-cell lung cancer patients fragment of encephalomyelitis; these patients developed sensory symptoms associated with paraneoplastic cerebellar with paraneoplastic cerebellar degeneration had P/Q-type voltage-gated calcium channel antibodies, and that most degeneration, and pathological findings of encephalomyelitis, cerebellar degeneration, dorsal root ganglionitis or degenerapatients did not have routine electrophysiological testing, suggest that the real prevalence of Lambert-Eaton myasthenic tion of posterior columns of the spinal cord. Brain et al. (1951) , in discussing the sensory deficits and pain of their syndrome is under-represented. The prevalence of P/Q-and N-type voltage-gated calcium channel antibodies is so high patient 4 stated that 'this symptom, as well as the degeneration of the dorsal columns when it occurs, links these cases with in HuAb negative paraneoplastic cerebellar degeneration patients (36% and 29%, respectively) as to suggest that those of polyneuritis associated with carcinoma described by Denny-Brown' (Denny-Brown, 1948 ). these antibodies may have a role in the pathogenesis of the cerebellar dysfunction. This possibility is supported by In contrast to the encephalomyelitis of the HuAb positive patients, no inflammatory infiltrates were identified in the the recent discovery that dysfunction of a brain-specific P/Q type voltage-gated calcium channel secondary to mutations cerebrum, brainstem, cerebellum and spinal cord of two paraneoplastic cerebellar degeneration patients without in the α1-subunit, results in ataxia (Ophoff et al., 1996) .
With the exception of the series of Brain and Wilkinson HuAb (autopsies 7 and 8). The absence of inflammatory infiltrates in these patients may have three explanations. (i) (1965), the lack of other studies focusing on small-cell lung cancer and paraneoplastic cerebellar degeneration may It could represent a burnt-out stage of the same inflammatory mechanism that affects patients with HuAb. This possiexplain that the frequent association with Lambert-Eaton myasthenic syndrome, although suspected, has not been bility seems unlikely because the interval from neurological symptoms to death was similar to that found in patients with defined until now. It is possible that this association is not restricted to paraneoplastic cerebellar degeneration, and that HuAb.
(ii) It could represent a different and non-inflammatory pathogenesis, similar to that reported in some patients with small-cell lung cancer patients with paraneoplastic encephalomyelitis and sensory neuropathy also have an increased Hodgkin's lymphoma, and cancer of the ovary and breast (Peterson et al., 1992; Sindic et al., 1993 ; Verschuuren et al., incidence of Lambert-Eaton myasthenic syndrome. Often patients with paraneoplastic encephalomyelitis and sensory 1996), or (iii) it could represent a short-lasting inflammatory disorder more limited and less maintained than that associated neuropathy who present with extracerebellar symptoms have early and severe sensory deficits, brainstem encephalopathy, with HuAb. We favour this last possibility, because the CSF of one of these patients had inflammatory changes in the autonomic dysfunction or lower motor neuron deficits (Dalmau et al., 1992b) , that make the detection of Lambertearly stages of the disease, and because a third patient without HuAb (autopsy 6), who died within 1 month of the course Eaton myasthenic syndrome more difficult than in those who present with paraneoplastic cerebellar degeneration alone. of the disease, had inflammatory infiltrates in the neuraxis (milder and more limited than those affecting HuAb positive Identification of Lambert-Eaton myasthenic syndrome is Although there appears to be a strong correlation between our serological classification of paraneoplastic cerebellar infiltrates in the neuraxis was noted by Brain et al. (1951) , referring to a patient reported by Munch-Petersen in 1947, degeneration and the morphological classification of Vick et al. (1969) and Henson and Urich (1982) , this correlation and by Julien et al. (1972) .
Our findings support the concepts and classification of is not perfect. Our study suggests that the pathological substrate of paraneoplastic cerebellar degeneration associated cortical cerebellar degeneration proposed by Henson and Urich (1982) . In a review of 44 pathologically reported with HuAb corresponds to the 'encephalomyelitic form' of paraneoplastic cerebellar degeneration, and adds serological cases of paraneoplastic cerebellar degeneration, these authors differentiated between those with absent or mild evidence that this entity is different from paraneoplastic cerebellar degeneration without HuAb. This second group, inflammation of the neuraxis (27 patients; 33% lung cancer) and those with prominent inflammation (17 patients; 47%
probably comprise several types of cerebellar degeneration, some without inflammatory mechanisms ('degenerative form lung cancer). To explain these pathological differences they outlined three possibilities: (i) the two groups are of Henson and Urich'), and some with inflammation only detectable in the early stages of the disease. A possible morphologically and pathogenetically separate entities; (ii) the second group represents the coexistence of two example of this latter group is case 1 of Brain and Wilkinson (1965) , considered by Henson and Urich (1982) to be a seemingly independent processes, one degenerative, the other inflammatory or (iii) both groups are variants of a single 'degenerative' form of paraneoplastic cerebellar degeneration, but whose autopsy showed perivascular cuffing only in some entity with active inflammation in some cases, burnt out in others. Henson and Urich (1982) considered that the evidence vessels of the left amygdaloid nucleus. Another example is our autopsy 6. This patient not only differed pathologically was insufficient to support any of their three views and, therefore, preferred 'to keep an open mind and adhere to but also serologically from the other two HuAb negative patients with post-mortem studies, since his serum harboured strictly morphological classification' (Henson and Urich, 1982) . However, the occurrence in some patients of Purkinje an antibody (CV2) reported in some cases of paraneoplastic encephalitis (Antoine et al., 1993; Honnorat et al., 1996) . cell degeneration independently of encephalomyelitis, or the reverse situation, led Vick et al. (1969) to suggest that Our views of paraneoplastic cerebellar degeneration in
